The role of interferon-λ locus polymorphisms in Hepatitis C and other infectious diseases

Journal of Innate Immunity

Volumn 7, Issue 3, 2015, Pages 231-242

  Griffiths, Samantha J ^a   Dunnigan, Cory M ^a   Russell, Clark D ^a   Haas, Jürgen G ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Autoimmunity; Cytokines; Epithelium; Hepatitis C virus; Host defence; IL28B; Immune response; Interferon ; Polymorphism; Single nucleotide polymorphism; Virology

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; LAMBDA INTERFERON; UNCLASSIFIED DRUG; CYTOKINE RECEPTOR; IFNLR1 PROTEIN, HUMAN;

ALLERGIC DISEASE; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BIOLOGICAL ACTIVITY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS RETINITIS; DISEASE ASSOCIATION; ETHNICITY; GENDER; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC POLYMORPHISM; HEPATITIS C; HERPES LABIALIS; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SIGNAL TRANSDUCTION; TROPICAL SPASTIC PARAPARESIS; ANIMAL; CHROMOSOME 19; GENETIC ASSOCIATION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY;

ANIMALS; CHROMOSOMES, HUMAN, PAIR 19; GENETIC LOCI; GENOME-WIDE ASSOCIATION STUDY; HEPATITIS C; HUMANS; IMMUNITY, INNATE; INTERFERONS; POLYMORPHISM, GENETIC; RECEPTORS, CYTOKINE;

EID: 84929028887     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000369902     Document Type: Review

References (105)

1. Thio CL, Thomas DL, Carrington M: Chronic viral hepatitis and the human genome. Hepatology 2000; 31: 819-827.
2. Zhang SY, Boisson-Dupuis S, Chapgier A, Yang K, Bustamante J, Puel A, Picard C, Abel L, Jouanguy E, Casanova JL: Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFNalpha/ beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev 2008; 226: 29-40.
3. Chapman SJ, Hill AV: Human genetic susceptibility to infectious disease. Nat Rev Genet 2012; 13: 175-188.
4. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, Mc-Hutchison JG, Goldstein DB: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
5. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J: IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
6. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
7. Taniguchi T, Takaoka A: The interferon-alpha/ beta system in antiviral responses: A multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 2002; 14: 111-116.
8. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP: ITN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77.
9. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR: A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45: 164-171.
10. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM: IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-68.
11. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R: Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 2007; 81: 7749-7758.
12. Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, Namiki H, Fujita T: Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 2007; 282: 7576-7581.
13. Diegelmann J, Beigel F, Zitzmann K, Kaul A, Goke B, Auernhammer CJ, Bartenschlager R, Diepolder HM, Brand S: Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS One 2010; 5:e15200.
14. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM: Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-1898.
15. Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, Gamero AM: IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/ STAT signaling activity. Cancer Biol Ther 2008; 7: 1109-1115.
16. Liu BS, Janssen HL, Boonstra A: IL-29 and IFNalpha differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNgamma receptor expression. Blood 2011; 117: 2385-2395.
17. Lee HC, Narayanan S, Park SJ, Seong SY, Hahn YS: Transcriptional regulation of IFNlambda genes in hepatitis C virus-infected hepatocytes via IRF-3IRF-7NF-B complex. J Biol Chem 2014; 289: 5310-5319.
18. Siegel R, Eskdale J, Gallagher G: Regulation of IFN-lambda1 promoter activity (IFN-lambda1/ IL-29) in human airway epithelial cells. J Immunol 2011; 187: 5636-5644.
19. Swider A, Siegel R, Eskdale J, Gallagher G: Regulation of interferon lambda-1 (IFNL1/ IFN-lambda1/IL-29) expression in human colon epithelial cells. Cytokine 2014; 65: 17-23.
20. Griffiths SJ, Koegl M, Boutell C, Zenner HL, Crump CM, Pica F, Gonzalez O, Friedel CC, Barry G, Martin K, Craigon MH, Chen R, Kaza LN, Fossum E, Fazakerley JK, Efstathiou S, Volpi A, Zimmer R, Ghazal P, Haas J: A systematic analysis of host factors reveals a Med23-interferon-lambda regulatory axis against herpes simplex virus type 1 replication. PLoS Pathog 2013; 9:e1003514.
21. Robek MD, Boyd BS, Chisari FV: Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79: 3851-3854.
22. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR: Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006; 80: 4501-4509.
23. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diebold J, Diepolder H, Adler B, Auernhammer CJ, Goke B, Dambacher J: IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine cmv infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 2005; 289: G960-G968.
24. Nordstrom I, Eriksson K: HHV-6B induces IFN-lambda1 responses in cord plasmacytoid dendritic cells through TLR9. PLoS One 2012; 7: e38683.
25. Hou W, Wang X, Ye L, Zhou L, Yang ZQ, Riedel E, Ho WZ: Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol 2009; 83: 3834-3842.
26. Okabayashi T, Kojima T, Masaki T, Yokota S, Imaizumi T, Tsutsumi H, Himi T, Fujii N, Sawada N: Type-III interferon, not type-I, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res 2011; 160: 360-366.
27. Jewell NA, Cline T, Mertz SE, Smirnov SV, Flano E, Schindler C, Grieves JL, Durbin RK, Kotenko SV, Durbin JE: Lambda interferon is the predominant interferon induced by influenza a virus infection in vivo. J Virol 2010; 84: 11515-11522.
28. Khaitov MR, Laza-Stanca V, Edwards MR, Walton RP, Rohde G, Contoli M, Papi A, Stanciu LA, Kotenko SV, Johnston SL: Respiratory virus induction of alpha-, beta-and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. Allergy 2009; 64: 375-386.
29. Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, Staeheli P: Interferon-lambda contributes to innate immunity of mice against influenza a virus but not against hepatotropic viruses. PLoS Pathog 2008; 4:e1000151.
30. Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, Falcone V, Sorgeloos F, Ehl S, Mayer D, Kochs G, Schwemmle M, Gunther S, Drosten C, Michiels T, Staeheli P: Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 2010; 84: 5670-5677.
31. Hamming OJ, Terczynska-Dyla E, Vieyres G, Dijkman R, Jorgensen SE, Akhtar H, Siupka P, Pietschmann T, Thiel V, Hartmann R: Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J 2013; 32: 3055-3065.
32. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, Dagnaes-Hansen F, Thomsen AR, Chen Z, Haugen H, Klucher K, Paludan SR: An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 2008; 180: 2474-2485.
33. Sommereyns C, Paul S, Staeheli P, Michiels T: IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008; 4: e1000017.
34. Pott J, Mahlakoiv T, Mordstein M, Duerr CU, Michiels T, Stockinger S, Staeheli P, Hornef MW: IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A 2011; 108: 7944-7949.
35. Russell CD, Griffiths SJ, Haas J: Interferon lambda genetic polymorphisms and viral infection: the tip of the iceberg? DNA Cell Biol 2014; 33: 60-63.
36. Pica F, Volpi A, Gaziano R, Garaci E: Interferon-lambda in immunocompetent individuals with a history of recurrent herpes labialis. Antivir Ther 2010; 15: 737-743.
37. Pasquali S, Mocellin S: The anticancer face of interferon alpha (IFN-alpha): from biology to clinical results, with a focus on melanoma. Curr Med Chem 2010; 17: 3327-3336.
38. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC: Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 2004; 279: 32269-32274.
39. Ding S, Khoury-Hanold W, Iwasaki A, Robek MD: Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth. PLoS Biol 2014; 12:e1001758.
40. Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, Okada M, Iwakura Y, Aiba S, Yamaya M: IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol 2007; 178: 5086-5098.
41. Tezuka Y, Endo S, Matsui A, Sato A, Saito K, Semba K, Takahashi M, Murakami T: Potential anti-tumor effect of IFN-lambda2 ( IL-28A) against human lung cancer cells. Lung Cancer 2012; 78: 185-192.
42. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
43. Ito K, Higami K, Masaki N, Sugiyama M, Mukaide M, Saito H, Aoki Y, Sato Y, Imamura M, Murata K, Nomura H, Hige S, Adachi H, Hino K, Yatsuhashi H, Orito E, Kani S, Tanaka Y, Mizokami M: The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol 2011; 49: 1853-1860.
44. Masaki N, Sugiyama M, Shimada N, Tanaka Y, Nakamuta M, Izumi N, Watanabe S, Tsubota A, Komatsu M, Masaki T, Enomoto N, Yoneda M, Murata K, Ito K, Koike K, Mizokami M: Pretreatment prediction of the outcome of response-guided peginterferon-alpha and ribavirin therapy for chronic hepatitis C. J Gastroenterol Hepatol 2014; 29: 1996-2005.
45. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, Duong FH, Gerlach T, Malinverni R, Moradpour D, Negro F, Mullhaupt B, Bochud PY: IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013; 210: 1109-1116.
46. Fujino H, Imamura M, Nagaoki Y, Kawakami Y, Abe H, Hayes CN, Kan H, Fukuhara T, Kobayashi T, Masaki K, Ono A, Nakahara T, Honda Y, Naeshiro N, Urabe A, Yokoyama S, Miyaki D, Murakami E, Kawaoka T, Hiraga N, Tsuge M, Hiramatsu A, Hyogo H, Aikata H, Takahashi S, Miki D, Ochi H, Ohishi W, Chayama K: Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1B chronic hepatitis C. J Gastroenterol 2014; 49: 1548-1556.
47. Meissner EG, Bon D, Prokunina-Olsson L, Tang W, Masur H, O'Brien TR, Herrmann E, Kottilil S, Osinusi A: IFNL4-G genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis 2014; 209: 1700-1704.
48. Dickson SP, Wang K, Krantz I, Hakonarson H, Goldstein DB: Rare variants create synthetic genome-wide associations. PLoS Biol 2010; 8:e1000294.
49. Stattermayer AF, Strassl R, Maieron A, Rutter K, Stauber R, Strasser M, Beinhardt S, Datz C, Scherzer TM, Steindl-Munda P, Gschwantler M, Trauner M, Hofer H, Ferenci P: Polymorphisms of interferon-4 and IL28B-effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther 2014; 39: 104-111.
50. Franco S, Aparicio E, Parera M, Clotet B, Tural C, Martinez MA: IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients. AIDS 2014; 28: 133-136.
51. Cui Q, Zhang YX, Su J, Chen X, Ding K, Lei N, Liu Y, Li J, Zhang Y, Yu RB: Genetic variation in IL28RA is associated with the outcomes of HCV infection in a high-risk Chinese population. Infect Genet Evol 2011; 11: 1682-1689.
52. Jimenez-Sousa MA, Berenguer J, Rallon N, Guzman-Fulgencio M, Lopez JC, Soriano V, Fernandez-Rodriguez A, Cosin J, Restrepo C, Garcia-Alvarez M, Miralles P, Benito JM, Resino S: IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/ HCV-coinfected patients. J Viral Hepat 2013; 20: 358-366.
53. Jin G, Kang H, Chen X, Dai D: Evaluation of the relationship between IL28B, IL10RB and IL28RA single-nucleotide polymorphisms and susceptibility to hepatitis C virus in Chinese Han population. Infect Genet Evol 2014; 21: 8-14.
54. Takahashi T: Interleukin 28B genetic polymorphism and hepatitis B virus infection. World J Gastroenterol 2014; 20: 12026-12030.
55. Seto WK, Wong DK, Kopaniszen M, Proitsi P, Sham PC, Hung IF, Fung J, Lai CL, Yuen MF: HLA-DP and IL28B polymorphisms: Influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis 2013; 56: 1695-1703.
56. Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Buster EH, Uitterlinden AG, Hansen BE, Chan HL, Janssen HL: Polymorphisms near IL28B and serologic response to peginterferon in HBeAgpositive patients with chronic hepatitis B. Gastroenterology 2012; 142: 513-520.e1.
57. Lampertico P, Vigano M, Cheroni C, Facchetti F, Invernizzi F, Valveri V, Soffredini R, Abrignani S, De Francesco R, Colombo M: IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013; 57: 890-896.
58. Lee IC, Lin CH, Huang YH, Huo TI, Su CW, Hou MC, Huang HC, Lee KC, Chan CC, Lin MW, Lin HC, Lee SD: IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. PLoS One 2013; 8:e58071.
59. Galmozzi E, Vigano M, Lampertico P: Systematic review with meta-analysis: Do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection? Aliment Pharmacol Ther 2014; 39: 569-578.
60. Lee DH, Lee JH, Kim YJ, Park NH, Cho Y, Lee YB, Yoo JJ, Lee M, Cho YY, Choi WM, Yu SJ, Yoon JH, Kim CY, Lee HS: Relationship between polymorphisms near the IL28B gene and spontaneous HBsAg seroclearance: A systematic review and meta-analysis. J Viral Hepat 2014; 21: 163-170.
61. Rauch A, Rohrbach J, Bochud PY: The recent breakthroughs in the understanding of host genomics in hepatitis C. Eur J Clin Invest 2010; 40: 950-959.
62. Smith KR, Suppiah V, O'Connor K, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Matthews G, Irving WL, Powell E, Riordan S, Ahlenstiel G, Stewart GJ, Bahlo M, George J, Booth DR: Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med 2011; 3: 57.
63. Hayes CN, Imamura M, Aikata H, Chayama K: Genetics of IL28B and HCV-response to infection and treatment. Nat Rev Gastroenterol Hepatol 2012; 9: 406-417.
64. Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, Nischalke HD, Nattermann J, Oldenburg J, Sauerbruch T, Spengler U: Interferon-lambda serum levels in hepatitis C. J Hepatol 2011; 54: 859-865.
65. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, Uchiyama H, Soejima Y, Shirabe K, Matsuura Y, Maehara Y: Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-1585, 1585.e1-3.
66. Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, Kim AY, Lauer GM, Chung RT, Peters MG, Kirk GD, Mehta SH, Cox AL, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Tobler LH, Busch MP, Alexander G, Rosen HR, Gao X, Abdel-Hamid M, Apps R, Carrington M, Thomas DL: Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med 2013; 158: 235-245.
67. Egli A, Levin A, Santer DM, Joyce M, O'Shea D, Thomas BS, Lisboa LF, Barakat K, Bhat R, Fischer KP, Houghton M, Tyrrell DL, Kumar D, Humar A: Immunomodulatory function of interleukin 28B during primary infection with cytomegalovirus. J Infect Dis 2014; 210: 717-727.
68. Honda M, Shirasaki T, Shimakami T, Sakai A, Horii R, Arai K, Yamashita T, Sakai Y, Okada H, Murai K, Nakamura M, Mizukoshi E, Kaneko S: Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes. Hepatology 2014; 59: 828-838.
69. Shi X, Pan Y, Wang M, Wang D, Li W, Jiang T, Zhang P, Chi X, Jiang Y, Gao Y, Zhong J, Sun B, Xu D, Jiang J, Niu J: IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One 2012; 7:e37054.
70. Sugiyama M, Tanaka Y, Wakita T, Nakanishi M, Mizokami M: Genetic variation of the IL-28B promoter affecting gene expression. PLoS One 2011; 6:e26620.
71. Estrabaud E, Lapalus M, Broet P, Appourchaux K, De Muynck S, Lada O, Martinot-Peignoux M, Bieche I, Valla D, Bedossa P, Marcellin P, Vidaud M, Asselah T: Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C. J Virol 2014; 88: 6394-6402.
72. Kamo Y, Ichikawa T, Miyaaki H, Uchida S, Yamaguchi T, Shibata H, Honda T, Taura N, Isomoto H, Takeshima F, Nakao K: Significance of miRNA-122 in chronic hepatitis C patients with serotype 1 on interferon therapy. Hepatol Res 2014, DOI: 10.1111/ hepr.12317.
73. McFarland AP, Horner SM, Jarret A, Joslyn RC, Bindewald E, Shapiro BA, Delker DA, Hagedorn CH, Carrington M, Gale M Jr, Savan R: The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol 2014; 15: 72-79.
74. Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, Monto A: Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 2012; 107: 669-689, quiz 690.
75. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hezode C, Esteban R: Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001.
76. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Brau N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P: Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898.
77. Bibert S, Wojtowicz A, Taffe P, Manuel O, Bernasconi E, Furrer H, Gunthard HF, Hoffmann M, Kaiser L, Osthoff M, Cavassini M, Bochud PY: The IFNL3/4 G variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. AIDS 2014; 28: 1885-1889.
78. Machmach K, Abad-Molina C, Romero-Sanchez MC, Abad MA, Ferrando-Martinez S, Genebat M, Pulido I, Viciana P, Gonzalez-Escribano MF, Leal M, Ruiz-Mateos E: IL28B single-nucleotide polymorphism rs12979860 is associated with spontaneous HIV control in white subjects. J Infect Dis 2013; 207: 651-655.
79. Safaeian M, Hildesheim A, Gonzalez P, Yu K, Porras C, Li Q, Rodriguez AC, Sherman ME, Schiffman M, Wacholder S, Burk R, Herrero R, Burdette L, Chanock SJ, Wang SS: Single nucleotide polymorphisms in the PRDX3 and RPS19 and risk of HPV persistence and cervical precancer/cancer. PLoS One 2012; 7: e33619.
80. Trevino A, Lopez M, Vispo E, Aguilera A, Ramos JM, Benito R, Roc L, Eiros JM, de Mendoza C, Soriano V: Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms. Clin Infect Dis 2012; 55:e1-e4.
81. Assone T, Souza FV, Gaester KO, Fonseca LA, Luiz Odo C, Malta F, Pinho JR, Goncalves Fde T, Duarte AJ, de Oliveira AC, Casseb J: IL28B gene polymorphism SNP rs8099917 genotype GG is associated with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in HTLV-1 carriers. PLoS Negl Trop Dis 2014; 8:e3199.
82. Kamihira S, Usui T, Ichikawa T, Uno N, Morinaga Y, Mori S, Nagai K, Sasaki D, Hasegawa H, Yanagihara K, Honda T, Yamada Y, Iwanaga M, Kanematu T, Nakao K: Paradoxical expression of IL-28B mRNA in peripheral blood in human T-cell leukemia virus type-1 mono-infection and co-infection with hepatitis C virus. Virol J 2012; 9: 40.
83. Scagnolari C, Midulla F, Riva E, Monteleone K, Solimini A, Bonci E, Cangiano G, Papoff P, Moretti C, Pierangeli A, Antonelli G: Evaluation of interleukin 28B single nucleotide polymorphisms in infants suffering from bronchiolitis. Virus Res 2012; 165: 236-240.
84. Selvaggi C, Pierangeli A, Fabiani M, Spano L, Nicolai A, Papoff P, Moretti C, Midulla F, Antonelli G, Scagnolari C: Interferon lambda 1-3 expression in infants hospitalized for RSV or HRV associated bronchiolitis. J Infect 2014; 68: 467-477.
85. Wei H, Wang S, Chen Q, Chen Y, Chi X, Zhang L, Huang S, Gao GF, Chen JL: Suppression of interferon lambda signaling by SOCS-1results in their excessive production during influenza virus infection results in their excessive production during influenza virus infection. PLoS Pathog 2014; 10: e1003845.
86. Zheng YW, Li H, Yu JP, Zhao H, Wang SE, Ren XB: Interferon-lambdas: special immunomodulatory agents and potential therapeutic targets. J Innate Immun 2013; 5: 209-218.
87. Gaudieri S, Lucas M, Lucas A, McKinnon E, Albloushi H, Rauch A, di Iulio J, Martino D, Prescott SL, Tulic MK: Genetic variations in IL28B and allergic disease in children. PLoS One 2012; 7:e30607.
88. Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M, Gallagher G: Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun 2007; 8: 254-261.
89. Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Ubel C, Kotenko SV, Sideras P, Lehr HA, Tepe M, Klucher KM, Doyle SE, Neurath MF, Finotto S, Andreakos E: IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med 2011; 3: 348-361.
90. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, Kebadze T, Mallia P, Stanciu LA, Parker HL, Slater L, Lewis-Antes A, Kon OM, Holgate ST, Davies DE, Kotenko SV, Papi A, Johnston SL: Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 2006; 12: 1023-1026.
91. Bullens DM, Decraene A, Dilissen E, Meyts I, De Boeck K, Dupont LJ, Ceuppens JL: Type III IFN-lambda mRNA expression in sputum of adult and school-aged asthmatics. Clin Exp Allergy 2008; 38: 1459-1467.
92. He S, Li T, Chen H, Ma W, Yao Q, Yang H, Wang H, Wang F, Zhao C, Yang P: Cd14+ cell-derived IL-29 modulates proinflammatory cytokine production in patients with allergic airway inflammation. Allergy 2011; 66: 238-246.
93. Lin SC, Kuo CC, Tsao JT, Lin LJ: Profiling the expression of interleukin (IL)-28 and IL-28 receptor alpha in systemic lupus erythematosus patients. Eur J Clin Invest 2012; 42: 61-69.
94. Wu Q, Yang Q, Lourenco E, Sun H, Zhang Y: Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity. Arthritis Res Ther 2011; 13:R88.
95. Li Y, Cheng H, Zuo XB, Sheng YJ, Zhou FS, Tang XF, Tang HY, Gao JP, Zhang Z, He SM, Lv YM, Zhu KJ, Hu DY, Liang B, Zhu J, Zheng XD, Sun LD, Yang S, Cui Y, Liu JJ, Zhang XJ: Association analyses identifying two common susceptibility loci shared by psoriasis and systemic lupus erythematosus in the Chinese Han population. J Med Genet 2013; 50: 812-818.
96. Rigante D, Mazzoni MB, Esposito S: The cryptic interplay between systemic lupus erythematosus and infections. Autoimmun Rev 2014; 13: 96-102.
97. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH: Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial. Clin Infect Dis 2008; 47: 1260-1269.
98. Roberts SK, Mitchell J, Leung R, Booth D, Bollipo S, Ostapowicz G, Sloss A, McCaughan GW, Dore GJ, Thompson A, Crawford DH, Sievert W, Weltman M, Cheng W, George J: Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies. J Gastroenterol Hepatol 2014; 29: 179-184
99. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, Morris MD, Hajarizadeh B, Amin J, Cox AL, Kim AY, Mc-Govern BH, Schinkel J, George J, Shoukry NH, Lauer GM, Maher L, Lloyd AR, Hellard M, Dore GJ, Prins M: The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 2014; 59: 109-120.
100. Russell CD, Griffiths SJ, Baillie JK, Haas J: Stratified infection medicine: A call to arms. Lancet Infect Dis 2014; 14: 451.
101. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI: Snap: A web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008; 24: 2938-2939.
102. Indolfi G, Mangone G, Bartolini E, Nebbia G, Calvo PL, Moriondo M, Tovo PA, de Martino M, Azzari C, Resti M: Comparative analysis of rs12979860 SNP of the IFNL3 gene in children with hepatitis C and ethnic matched controls using 1000 Genomes Project data. PLoS One 2014; 9:e85899.
103. Venegas M, Villanueva RA, Gonzalez K, Brahm J: IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients. World J Gastroenterol 2011; 17: 3636-3639.
104. Rao HY, Sun DG, Jiang D, Yang RF, Guo F, Wang JH, Liu F, Zhang HY, Zhang HH, Du SC, Jin Q, Qin H, Lok AS, Wei L: IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat 2012; 19: 173-181.
105. di Iulio J, Ciuffi A, Fitzmaurice K, Kelleher D, Rotger M, Fellay J, Martinez R, Pulit S, Furrer H, Gunthard HF, Battegay M, Bernasconi E, Schmid P, Hirschel B, Barnes E, Klenerman P, Telenti A, Rauch A: Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology 2011; 53: 1446-1454.